The first group consist of BRCA1/2-deficient breast cancers with T cell-inflamed signature score above the median (Thigh) while the second group consist of BRCA1/2-deficient breast cancers with T cell-inflamed signature score equal to or below the median (Tlow). This evidence concerns the gene BRCA1 and breast carcinoma.